FRM
CSTL icon

Fox Run Management’s Castle Biosciences CSTL Stock Holding History

Fox Run Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,247
Closed -$618K – 996
2026
Q1 		$618K Buy
26,247
+4,363
+20% +$143K 0.11% 350
2025
Q4 		$851K Buy
21,884
+8,064
+58% +$260K 0.13% 274
2025
Q3 		$315K Buy
+13,820
New +$281K 0.05% 663
2025
Q1 		– Sell
-10,716
Closed -$286K – 962
2024
Q4 		$286K Buy
+10,716
New +$326K 0.05% 652
2024
Q1 		– Sell
-12,150
Closed -$262K – 806
2023
Q4 		$262K Buy
+12,150
New +$214K 0.07% 544

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's CSTL Position: Q2 2026 in Review

Fox Run Management sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 26,247 shares — an estimated $618K sold.

Fox Run Management first reported a position in CSTL in Q4 2023 and held it in 5 quarters. The position peaked at $851K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Fox Run Management reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 26,247 Castle Biosciences shares in Q2 2026, an estimated $618K.
  • Fox Run Management first reported a position in Castle Biosciences in Q4 2023 and held it in 5 quarters.
  • Fox Run Management's Castle Biosciences position peaked at $851K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.